Abstract:Abstract Autophagy is an evolutionarily conserved process involving degradation of cellular components in lysosomes to maintain protein and organelle quality control, and temporarily sustain cell viability in response to stressful stimuli. Several studies have demonstrated the dual role of autophagy in tumorigenesis as both a tumor suppressor and a protector of cancer cell survival under stress. It is well recognized that anticancer therapies, such as chemotherapy and irradiation (RT), induce autophagy as a pro-survival response, likely resulting in therapeutic resistance. Therefore, concurrent autophagy inhibition as a chemo- and RT-sensitizer has generated great interest in cancer therapy. We generated Beclin1+/+ and Beclin1+/- immortalized mouse mammary epithelial cells (iMMECs) stably expressing the apoptosis inhibitor BCL-2 and the autophagy marker EGFP-LC3 to investigate how acute autophagy inhibition and chronic autophagy deregulation impact tumor sensitivity to anticancer drugs commonly used against breast cancer. We also used human cancer cell lines, including MCF-7, PANC-1, MIA PaCa-2 and HCT-116 cells, to explore whether pharmacologic autophagy inhibition or genetic knockdown of autophagy regulators exhibits a synergistic anticancer effect with newer antineoplastic drugs, such as mTOR inhibitors (CCI-779 and RAD001) and novel antimicrotubule agents (ixabepilone). Treatment efficacy was evaluated by clonogenic survival and cytotoxicity assays in 2D- and 3D-epithelial cell culture in vitro and by tumor responsiveness assays in mice in vivo. Autophagy inhibition sensitized Beclin1+/+ apoptosis-defective iMMECs to doxorubicin, but not to paclitaxel, and had an even greater impact on autophagy-deficient cells. Moreover, autophagy inhibition via choloroquine or Beclin1 knockdown enhanced the treatment efficacy of mTOR inhibitors on MCF-7, PANC-1, MIA PaCa-2 and HCT116 cells in vitro and in xenograft tumors in nude mice in vivo. These studies provide insight into how autophagy functional status in tumors impacts treatment responsiveness and into how to best incorporate pharmacologic autophagy modulation in the decision tree for cancer treatment. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3545. doi:10.1158/1538-7445.AM2011-3545

Autophagy Inhibition in Childhood Nephroblastoma and the Therapeutic Significance.

Abstract 3545: Autophagy Inhibition As a Therapeutic Strategy in Cancer

Autophagy Regulators As Potential Cancer Therapeutic Agents: A Review

Targeting autophagy as a therapeutic strategy in pediatric acute lymphoblastic leukemia

Inhibition of Autophagy Potentiates the Efficacy of Gli Inhibitor GANT-61 in MYCN-amplified Neuroblastoma Cells

Inhibition of Autophagy May Suppress the Development of Hepatoblastoma

High Mobility Group Box 1-Mediated Autophagy Promotes Neuroblastoma Cell Chemoresistance

Autophagy As a Therapeutic Target in Cancer

Autophagic degradation of CDK2 and CDK4 is responsible for NVP-BEZ235-induced G0/G1 cell cycle arrest in neuroblastoma

A potential strategy for bladder cancer treatment: inhibiting autophagy to enhance antitumor effects of Nectin-4-MMAE

Role and Regulation of Autophagy in Cancer

Inhibiting Autophagy in Renal Cell Cancer and the Associated Tumor Endothelium

Identification of an Autophagy-Related Risk Signature Correlates With Immunophenotype and Predicts Immune Checkpoint Blockade Efficacy of Neuroblastoma

Autophagy flux in bladder cancer: Cell death crosstalk, drug and nanotherapeutics

Autophagy in Cancer Chemoprevention: Identification of Novel Autophagy Modulators with Anticancer Potential

Lysosomal proteases as potential targets for the induction of apoptotic cell death in human neuroblastomas

Autophagy Modulation in Bladder Cancer Development and Treatment

Autophagic degradation of CDK4 is responsible for G0/G1 cell cycle arrest in NVP-BEZ235-treated neuroblastoma

Autophagy collaborates with ubiquitination to downregulate oncoprotein E2A/Pbx1 in B-cell acute lymphoblastic leukemia

Effect of preoperative transarterial chemoembolization on nephroblastoma

Β2‑adrenergic Receptor Signaling Promotes Neuroblastoma Cell Proliferation by Activating Autophagy.